Development and validation of a clinical and genetic model for predicting risk of severe COVID-19
Open Access
- 2 July 2021
- journal article
- research article
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 149, 1-32
- https://doi.org/10.1017/s095026882100145x
Abstract
Clinical and genetic risk factors for severe coronavirus disease 2019 (COVID-19) are often considered independently and without knowledge of the magnitudes of their effects on risk. Using severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) positive participants from the UK Biobank, we developed and validated a clinical and genetic model to predict risk of severe COVID-19. We used multivariable logistic regression on a 70% training dataset and used the remaining 30% for validation. We also validated a previously published prototype model. In the validation dataset, our new model was associated with severe COVID-19 (odds ratio per quintile of risk = 1.77, 95% confidence interval (CI) 1.64–1.90) and had acceptable discrimination (area under the receiver operating characteristic curve = 0.732, 95% CI 0.708–0.756). We assessed calibration using logistic regression of the log odds of the risk score, and the new model showed no evidence of over- or under-estimation of risk (α = −0.08; 95% CI −0.21−0.05) and no evidence or over-or under-dispersion of risk (β = 0.90, 95% CI 0.80–1.00). Accurate prediction of individual risk is possible and will be important in regions where vaccines are not widely available or where people refuse or are disqualified from vaccination, especially given uncertainty about the extent of infection transmission among vaccinated people and the emergence of SARS-CoV-2 variants of concern.Keywords
This publication has 21 references indexed in Scilit:
- Trans-ancestry analysis reveals genetic and nongenetic associations with COVID-19 susceptibility and severityNature Genetics, 2021
- Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deploymentThe Lancet, 2021
- Genetic Variants of SARS-CoV-2—What Do They Mean?JAMA, 2021
- Maximising benefit, reducing inequalities and ensuring deliverability: Prioritisation of COVID-19 vaccination in the UKThe Lancet Regional Health - Europe, 2020
- Genomewide Association Study of Severe Covid-19 with Respiratory FailureThe New England Journal of Medicine, 2020
- Factors associated with COVID-19-related death using OpenSAFELYNature, 2020
- Structural analysis of TIFA: Insight into TIFA-dependent signal transduction in innate immunityScientific Reports, 2020
- GATA transcription factors in development and diseaseDevelopment, 2018
- Second-generation PLINK: rising to the challenge of larger and richer datasetsGigaScience, 2015
- GATA-3 Function in Innate and Adaptive ImmunityImmunity, 2014